MAR – Page 3 – Alligator Bioscience

2021-09-02

Regulatory

Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...

2021-08-18

Regulatory

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...

2021-06-04

Regulatory

Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...

2021-04-22

Regulatory

Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding C ...

2021-03-18

Regulatory

Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...

2021-01-27

Regulatory

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...

2020-12-15

Regulatory

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...

2020-10-27

Regulatory

Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...

2020-10-22

Regulatory

Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...